Study: NCT00874939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 7.5 mg
Description: 4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0249 25 mg
Description: 5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 5mg
Description: One 5 mg tablet, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 5mg
Description: One 5 mg tablet, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 5mg
Description: One 5 mg tablet, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 5mg
Description: One 5 mg tablet, single oral dose during each crossover period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil 5mg
Description: One 5 mg tablet, single oral dose during each crossover period